Status:
UNKNOWN
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function
Lead Sponsor:
National Institute on Aging (NIA)
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
21-75 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if treatment with a drug called fenofibrate, which is a PPAR-alpha agonist and controls how the heart metabolizes fats, will reverse the age-related decline i...
Detailed Description
In older Americans, cardiovascular disease is the leading cause of death and disability. It has been shown recently that with aging the human heart exhibits a decline in myocardial fatty acid utilizat...
Eligibility Criteria
Inclusion
- Aged 60-75 or 21-35
- Normal glucose tolerance test
- Normal plasma fasting lipid panel (fasting total cholesterol less than 220 mg/dL)
- Normal rest/stress echocardiogram
- BMI (body mass index) less than 30 kg/m2
- Must be sedentary (active, but do not engage in regular exercise or jobs that require strenuous exertion)
Exclusion
- Coronary artery disease
- High blood pressure
- Current smoker
- Diabetes mellitus
- Cardiovascular disease (signs and symptoms of any kind)
- Pregnant or breastfeeding
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00627653
Start Date
October 1 2005
End Date
December 1 2009
Last Update
February 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110